Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

ClinicalTrials.gov ID: NCT01500772

Public ClinicalTrials.gov record NCT01500772. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Single-arm Trial Evaluating the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-IFNα2a/RBV) in Protease Inhibitor Treatment Failure Patients With Chronic Hepatitis C Genotype 1

Study identification

NCT ID
NCT01500772
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Debiopharm International SA
Industry
Enrollment
6 participants

Conditions and interventions

Conditions

Interventions

  • Alisporivir Drug
  • Peginterferon alfa-2a Drug
  • Ribavirin Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2012
Primary completion
Apr 30, 2012
Completion
Apr 30, 2012
Last update posted
Jul 31, 2016

2012

United States locations

U.S. sites
26
U.S. states
13
U.S. cities
22
Facility City State ZIP Site status
Novartis Investigative Site Phoenix Arizona 85054
Novartis Investigative Site Bakersfield California 93301
Novartis Investigative Site Los Angeles California 90033
Novartis Investigative Site Palo Alto California 95128
Novartis Investigative Site Sacramento California 95817
Novartis Investigative Site San Diego California 92114
Novartis Investigative Site San Diego California 92128
Novartis Investigative Site Ventura California 93003
Novartis Investigational site Bradenton Florida 34209
Novartis Investigative Site Bradenton Florida 34209
Novartis Investigative Site Miami Florida 33136
Novartis Investigative Site Wellington Florida 33414
Novartis Investigative Site Chicago Illinois 60611
Novartis Investigative Site Baltimore Maryland 21229
Novartis Investigative Site Brockton Massachusetts 02302
Novartis Investigative Site Minneapolis Minnesota 55404
Novartis Investigative Site St Louis Missouri 63110
Novartis Investigative Site New York New York 10021
Novartis Investigative Site New York New York 10029
Novartis Investigative Site New York New York 10032
Novartis Investigative Site Cincinnati Ohio 45267
Novartis Investigative Site Providence Rhode Island 02905
Novartis Investigative Site Arlington Texas 76012
Novartis Investigative Site Dallas Texas 75246
Novartis Investigative Site Alexandria Virginia 22306
Novartis Investigative Site Newport News Virginia 23602

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01500772, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2016 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01500772 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →